Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 5 | 2023 | 49 | 1.930 |
Why?
|
| Pregnancy | 39 | 2025 | 3147 | 1.870 |
Why?
|
| Cesarean Section | 5 | 2022 | 157 | 1.350 |
Why?
|
| Pregnancy Complications | 5 | 2021 | 352 | 1.320 |
Why?
|
| Obesity | 8 | 2022 | 1018 | 1.080 |
Why?
|
| Obstetrics | 3 | 2018 | 123 | 1.010 |
Why?
|
| Gestational Age | 8 | 2024 | 333 | 0.960 |
Why?
|
| Postpartum Period | 3 | 2022 | 159 | 0.900 |
Why?
|
| Breast Feeding | 3 | 2021 | 100 | 0.760 |
Why?
|
| Cost-Benefit Analysis | 7 | 2015 | 492 | 0.740 |
Why?
|
| Infant, Newborn | 10 | 2025 | 2479 | 0.700 |
Why?
|
| Overweight | 2 | 2021 | 120 | 0.680 |
Why?
|
| Female | 43 | 2025 | 48702 | 0.650 |
Why?
|
| Hirschsprung Disease | 1 | 2020 | 13 | 0.640 |
Why?
|
| Tracheal Diseases | 1 | 2020 | 14 | 0.640 |
Why?
|
| Fetal Diseases | 1 | 2020 | 75 | 0.630 |
Why?
|
| Intellectual Disability | 1 | 2021 | 195 | 0.620 |
Why?
|
| Placenta | 4 | 2023 | 189 | 0.610 |
Why?
|
| Surgical Wound | 1 | 2019 | 7 | 0.610 |
Why?
|
| Patient Discharge | 1 | 2022 | 356 | 0.600 |
Why?
|
| Electrocardiography | 1 | 2022 | 493 | 0.600 |
Why?
|
| Tissue Adhesives | 1 | 2019 | 24 | 0.600 |
Why?
|
| Child Development | 1 | 2021 | 166 | 0.600 |
Why?
|
| Labor, Obstetric | 1 | 2019 | 47 | 0.590 |
Why?
|
| Pregnancy in Diabetics | 2 | 2022 | 41 | 0.590 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2019 | 57 | 0.590 |
Why?
|
| Postpartum Hemorrhage | 2 | 2022 | 28 | 0.580 |
Why?
|
| Abnormalities, Multiple | 1 | 2020 | 237 | 0.580 |
Why?
|
| Health Care Costs | 3 | 2014 | 251 | 0.570 |
Why?
|
| Suture Techniques | 1 | 2019 | 142 | 0.560 |
Why?
|
| Aneuploidy | 2 | 2016 | 59 | 0.530 |
Why?
|
| Prenatal Diagnosis | 2 | 2016 | 110 | 0.520 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 109 | 0.500 |
Why?
|
| Pre-Eclampsia | 3 | 2025 | 261 | 0.500 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2024 | 96 | 0.490 |
Why?
|
| Health Personnel | 1 | 2018 | 234 | 0.480 |
Why?
|
| Term Birth | 1 | 2015 | 8 | 0.470 |
Why?
|
| Humans | 46 | 2025 | 93515 | 0.460 |
Why?
|
| Adult | 28 | 2025 | 27918 | 0.450 |
Why?
|
| Anesthesia, Epidural | 1 | 2015 | 33 | 0.450 |
Why?
|
| Body Mass Index | 7 | 2021 | 811 | 0.440 |
Why?
|
| Cesarean Section, Repeat | 1 | 2014 | 3 | 0.420 |
Why?
|
| Trial of Labor | 1 | 2014 | 6 | 0.420 |
Why?
|
| Labor Stage, Second | 3 | 2022 | 6 | 0.420 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2014 | 8 | 0.410 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2014 | 45 | 0.400 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 116 | 0.400 |
Why?
|
| Prospective Studies | 10 | 2023 | 4560 | 0.400 |
Why?
|
| Serpins | 2 | 2014 | 31 | 0.380 |
Why?
|
| Nerve Growth Factors | 2 | 2014 | 53 | 0.380 |
Why?
|
| Hepatitis C | 2 | 2005 | 182 | 0.380 |
Why?
|
| Misoprostol | 2 | 2024 | 21 | 0.360 |
Why?
|
| Labor, Induced | 2 | 2024 | 32 | 0.360 |
Why?
|
| Glucose Tolerance Test | 2 | 2023 | 232 | 0.360 |
Why?
|
| Eye Proteins | 2 | 2014 | 130 | 0.350 |
Why?
|
| Pregnancy Outcome | 4 | 2024 | 268 | 0.350 |
Why?
|
| Cardiotocography | 2 | 2022 | 7 | 0.350 |
Why?
|
| Oxytocics | 2 | 2022 | 25 | 0.330 |
Why?
|
| DNA | 1 | 2016 | 1265 | 0.320 |
Why?
|
| Hospitalization | 1 | 2015 | 937 | 0.310 |
Why?
|
| Cohort Studies | 9 | 2024 | 3054 | 0.290 |
Why?
|
| Stillbirth | 1 | 2008 | 14 | 0.280 |
Why?
|
| Infant | 3 | 2021 | 3220 | 0.280 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2024 | 71 | 0.260 |
Why?
|
| Quality Improvement | 2 | 2022 | 485 | 0.260 |
Why?
|
| Weight Gain | 3 | 2020 | 128 | 0.260 |
Why?
|
| Placenta Growth Factor | 2 | 2024 | 81 | 0.240 |
Why?
|
| Retrospective Studies | 10 | 2024 | 10164 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2024 | 105 | 0.240 |
Why?
|
| Mass Screening | 3 | 2013 | 696 | 0.230 |
Why?
|
| Delivery, Obstetric | 2 | 2022 | 121 | 0.230 |
Why?
|
| Adiponectin | 1 | 2025 | 21 | 0.220 |
Why?
|
| Vitamin E | 1 | 2025 | 34 | 0.220 |
Why?
|
| Ascorbic Acid | 1 | 2025 | 40 | 0.220 |
Why?
|
| Fetal Blood | 1 | 2025 | 95 | 0.220 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2005 | 62 | 0.220 |
Why?
|
| Vitamins | 1 | 2025 | 85 | 0.210 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2004 | 37 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2025 | 131 | 0.210 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 2 | 2024 | 11 | 0.210 |
Why?
|
| Antioxidants | 1 | 2025 | 231 | 0.200 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2003 | 16 | 0.200 |
Why?
|
| Abortion, Induced | 2 | 2024 | 162 | 0.200 |
Why?
|
| Bupivacaine | 1 | 2003 | 48 | 0.190 |
Why?
|
| C-Peptide | 1 | 2023 | 184 | 0.190 |
Why?
|
| Analgesia, Epidural | 1 | 2003 | 42 | 0.190 |
Why?
|
| Sex | 1 | 2002 | 5 | 0.180 |
Why?
|
| Logistic Models | 3 | 2022 | 1243 | 0.180 |
Why?
|
| Labor Stage, First | 1 | 2022 | 3 | 0.180 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 484 | 0.180 |
Why?
|
| Fetal Hypoxia | 1 | 2022 | 14 | 0.180 |
Why?
|
| Fetus | 1 | 2023 | 236 | 0.180 |
Why?
|
| Decision Trees | 3 | 2014 | 64 | 0.180 |
Why?
|
| Checklist | 1 | 2022 | 73 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2014 | 156 | 0.170 |
Why?
|
| Premature Birth | 1 | 2023 | 129 | 0.170 |
Why?
|
| Wechsler Scales | 1 | 2021 | 17 | 0.170 |
Why?
|
| Oxytocin | 1 | 2022 | 75 | 0.170 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2022 | 83 | 0.170 |
Why?
|
| Thinness | 1 | 2021 | 45 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 72 | 0.170 |
Why?
|
| Gynecology | 1 | 2002 | 130 | 0.160 |
Why?
|
| Glucose | 1 | 2023 | 692 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2022 | 379 | 0.160 |
Why?
|
| Goals | 1 | 2020 | 67 | 0.160 |
Why?
|
| United States | 5 | 2024 | 7622 | 0.150 |
Why?
|
| Wound Closure Techniques | 1 | 2019 | 15 | 0.150 |
Why?
|
| Fetofetal Transfusion | 1 | 2019 | 8 | 0.150 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2019 | 24 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2025 | 985 | 0.150 |
Why?
|
| Pain Management | 1 | 2020 | 180 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2018 | 21 | 0.140 |
Why?
|
| Prenatal Care | 3 | 2013 | 80 | 0.140 |
Why?
|
| Exercise | 2 | 2018 | 353 | 0.130 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 102 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 711 | 0.130 |
Why?
|
| Biomarkers | 1 | 2024 | 1910 | 0.130 |
Why?
|
| Risk Factors | 3 | 2024 | 5899 | 0.130 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 185 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2018 | 236 | 0.120 |
Why?
|
| Counseling | 1 | 2018 | 168 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2012 | 565 | 0.120 |
Why?
|
| Fathers | 1 | 2016 | 44 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 513 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 2016 | 71 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2802 | 0.120 |
Why?
|
| Urolithiasis | 1 | 2015 | 4 | 0.120 |
Why?
|
| Ureteroscopy | 1 | 2015 | 37 | 0.110 |
Why?
|
| Male | 6 | 2023 | 44557 | 0.110 |
Why?
|
| Physicians | 1 | 2002 | 682 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2016 | 296 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 3 | 2023 | 63 | 0.110 |
Why?
|
| Maternal Mortality | 1 | 2014 | 15 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2021 | 3829 | 0.100 |
Why?
|
| Infant Mortality | 1 | 2014 | 66 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 557 | 0.100 |
Why?
|
| Models, Economic | 1 | 2014 | 61 | 0.100 |
Why?
|
| Patient Simulation | 1 | 2013 | 48 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 191 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 660 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2014 | 91 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2014 | 69 | 0.100 |
Why?
|
| Rubella | 1 | 2013 | 1 | 0.100 |
Why?
|
| Rubella virus | 1 | 2013 | 1 | 0.100 |
Why?
|
| Weight Loss | 1 | 2015 | 234 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 624 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2013 | 122 | 0.090 |
Why?
|
| Stents | 1 | 2015 | 409 | 0.090 |
Why?
|
| Abortion, Habitual | 1 | 2012 | 31 | 0.090 |
Why?
|
| Young Adult | 6 | 2025 | 6930 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1053 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2014 | 270 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2014 | 477 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 398 | 0.080 |
Why?
|
| Prostate | 1 | 2014 | 416 | 0.080 |
Why?
|
| Echocardiography | 1 | 2014 | 745 | 0.080 |
Why?
|
| Adolescent | 5 | 2023 | 9606 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2013 | 372 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1917 | 0.070 |
Why?
|
| Age Distribution | 2 | 2007 | 206 | 0.070 |
Why?
|
| Time Factors | 3 | 2024 | 5410 | 0.070 |
Why?
|
| Probability | 2 | 2013 | 355 | 0.070 |
Why?
|
| Preimplantation Diagnosis | 1 | 2007 | 6 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 822 | 0.070 |
Why?
|
| Live Birth | 1 | 2007 | 22 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2007 | 101 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2007 | 98 | 0.060 |
Why?
|
| Middle Aged | 3 | 2023 | 27573 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2007 | 41 | 0.060 |
Why?
|
| Women's Health | 1 | 2007 | 107 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 291 | 0.060 |
Why?
|
| Postnatal Care | 1 | 2005 | 30 | 0.050 |
Why?
|
| Markov Chains | 1 | 2005 | 135 | 0.050 |
Why?
|
| Uterine Rupture | 1 | 2024 | 7 | 0.050 |
Why?
|
| Chorioamnionitis | 1 | 2024 | 23 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2013 | 1090 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 373 | 0.050 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2003 | 30 | 0.050 |
Why?
|
| Parity | 1 | 2003 | 97 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 55 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 624 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 181 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 1775 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2022 | 58 | 0.050 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2022 | 30 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2014 | 2562 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 181 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 608 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 775 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2003 | 373 | 0.040 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2021 | 35 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 356 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 33 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 1701 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2020 | 61 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 63 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1321 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 1713 | 0.040 |
Why?
|
| Pregnancy, Twin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 315 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1531 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 867 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 276 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 873 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1050 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 828 | 0.030 |
Why?
|
| Suburban Population | 1 | 2016 | 6 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 38 | 0.030 |
Why?
|
| Phenotype | 1 | 2022 | 2544 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1914 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 3830 | 0.030 |
Why?
|
| Saliva | 1 | 2016 | 124 | 0.030 |
Why?
|
| Foreign-Body Migration | 1 | 2015 | 32 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 170 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 234 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2007 | 9099 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 81 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 103 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2016 | 342 | 0.020 |
Why?
|
| Embryo Loss | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 71 | 0.020 |
Why?
|
| Cost Savings | 1 | 2012 | 68 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 917 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 350 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1741 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2007 | 46 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3911 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2007 | 193 | 0.010 |
Why?
|
| Illinois | 1 | 2007 | 520 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 1953 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3476 | 0.010 |
Why?
|
| Child | 1 | 2013 | 7355 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 28155 | 0.010 |
Why?
|